CREATE TRANSFORMATIVE MEDICINES

Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian...

As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use.

eTheRNA used the NanoAssemblr® NxGen technology because we could perform precise tuning of the size of our nanoparticles to target the optimal immunogenicity in vivo.

The scalability and reproducibility of PNI’s NanoAssemblr platform allowed us to move into GMP manufacturing with greater control over the process and increased precision in the final product compared to our previous macromixing process, allowing acceleration of our time to commercialization.

In terms of ease of operation it almost doesn’t compare. The Ignite is really, really smooth. It genuinely takes about half the time to make the same subset of particles when we’re using the same machines (NABT and Ignite). It really does feel like the benchtop came out, it was out for a few years, ...

The NanoAssemblr Blaze from Precision NanoSystems is very good for the rapid scale-up of nanoparticle-based formulations. We were able to seamlessly transition our formulation developed on the NanoAssemblr Benchtop to the Blaze instrument and make large scale batches on the Blaze. The Blaze instrume...

The ease, reproducibility, and the robustness of PNI’s products is amazing compared to what we previously had used, and that’s been a real enabling factor for Guide as we’ve continued to grow over the last year and a half.

Of particular note is LM03PE which had IgG levels of almost 108 ng/mL. We've never seen antibody levels this high.

We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens.